Qudexy XR
ApprovedSmall molecule
Qudexy XR is one of 26 small molecule programs targeting Migraine. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
357 competitors in Migraine
#DrugCompanyPhaseTrials
1Aimovig
AmgenPreclinical
Qudexy XR
UUpsher-Smith Laboratories
Approved
Emgality
Eli LillyPreclinical
Vyepti
LundbeckPreclinical
Savella
AbbViePreclinical
Bayer Aspirin
BayerPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Cervidil
PfizerPreclinical
Viagra
VViatris Specialty LLC
Preclinical
Pristiq
PPrism Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Qudexy XR. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUpsher-Smith Laboratories